Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
103,605
Roche Holding AG News & Analysis
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
10 global stocks for a recession
These undervalued stocks come from high-quality companies in defensive sectors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,693.90 | 60.80 | 0.70% |
| CAC 40 | 7,255.01 | 41.69 | 0.58% |
| DAX 40 | 19,322.59 | 176.42 | 0.92% |
| Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
| FTSE 100 | 8,262.08 | 112.81 | 1.38% |
| HKSE | 19,309.80 | 79.83 | 0.42% |
| NASDAQ | 19,003.65 | 31.23 | 0.16% |
| Nikkei 225 | 38,868.68 | 584.83 | 1.53% |
| NZX 50 Index | 13,132.74 | 90.84 | 0.70% |
| S&P 500 | 5,969.34 | 20.63 | 0.35% |
| S&P/ASX 200 | 8,450.20 | 56.40 | 0.67% |
| SSE Composite Index | 3,284.48 | 17.29 | 0.53% |